Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera
-
Published:2005-04-01
Issue:10
Volume:23
Page:2224-2232
-
ISSN:0732-183X
-
Container-title:Journal of Clinical Oncology
-
language:en
-
Short-container-title:JCO
Author:
Marchioli Roberto1, Finazzi Guido1, Landolfi Raffaele1, Kutti Jack1, Gisslinger Heinz1, Patrono Carlo1, Marilus Raphael1, Villegas Ana1, Tognoni Gianni1, Barbui Tiziano1
Affiliation:
1. From the Consorzio Mario Negri Sud, Santa Maria Imbaro; the Catholic University School of Medicine, and the University of Rome “La Sapienza,” Rome; the Ospedali Riuniti, Bergamo, Italy; the Sahlgrenska Hospital, Göteborg, Sweden; the Department of Hematology and Blood Coagulation, University of Vienna, Austria; the Tel-Aviv Souraski Medical Center, Tel-Aviv, Israel; and the Hospital Universitario S Carlos, Madrid, Spain
Abstract
Purpose The clinical course of polycythemia vera is often complicated by thrombosis as well as by the possible transition to myeloid metaplasia with myelofibrosis or acute myeloid leukemia. The aim of this study was to assess the rate of these complications in subjects receiving currently recommended treatments. Patients and Methods Overall, 1,638 patients from 12 countries were enrolled onto a large, prospective multicenter project aimed at describing the clinical history of polycythemia vera for the following outcomes: survival, the cumulative rate of cardiovascular death and thrombosis, the cumulative rate of leukemia, myelodysplasia, and myelofibrosis. The mean duration of the disease at entry and the duration of the follow-up were 4.9 and 2.7 years, respectively. Results The overall mortality rate of 3.7 deaths per 100 persons per year resulted from a moderate risk of cardiovascular death and a high risk of death from noncardiovascular causes (mainly hematologic transformations). Age older than 65 years and a positive history of thrombosis were the most important predictors of cardiovascular events. Antiplatelet therapy, but not cytoreductive treatment, was significantly associated with a lower risk of cardiovascular events. We found a consistent association between age and risk of leukemia, and between duration of the disease with risk of myelofibrosis. Conclusion The European Collaboration on Low-Dose Aspirin in Polycythemia Vera study documents that large international collaborative studies are feasible in this field, in which few epidemiologic data are available. The persistently high mortality rate from hematologic malignancies characterizes the unmet therapeutic need of polycythemic patients and suggests a priority for future studies in this disease.
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Reference23 articles.
1. Wasserman LR, Berk PD, Berlin NI: Polycythemia vera and the myeloproliferative disorders . Philadelphia, PA, W.B. Saunders, 1995 2. Polycythemia vera: myths, mechanisms, and management 3. Chievitz E, Thiede T: Complications and causes of death in polycythemia vera. Acta Med Scand 172: 513,1962-523, 4. Increased Incidence of Acute Leukemia in Polycythemia Vera Associated with Chlorambucil Therapy 5. Pearson TC, Messinezy M, Westwood N, et al: A polycythemia vera update: Diagnosis, pathobiology, and treatment, in Schechter GP, Berlinen N, Telen MJ (eds): Hematology 2000 American Society of Hematology Education Program Book . Washington, DC, American Society of Hematology, pp51,2000-68
Cited by
585 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|